Ticagrelor: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NICE (England), among others, recommended or restricted ticagrelor, while CONITEC (Brazil) and PBAC (Australia) did not recommend it.
The file has been open for more than a decade: 12.5 years separate the first record, 10 Jan 2011 at AWMSG (Wales), from the most recent, 2023 at PBAC (Australia).
SMC (Scotland) changed its position: recommended on 9 May 2011, not recommended by 10 Apr 2017.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The programme is broad: 8 distinct indication wordings are recorded for ticagrelor by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 20 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ticagrelor, on 10 Jan 2011; PBAC (Australia) did not open a file until 2023 — an unusually long tail of 12.5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 7 years in total.
7 of the 9 agencies here assessed ticagrelor more than once, PHARMAC (New Zealand) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for ticagrelor.
The full ledger for ticagrelor reads 10 recommended, 5 not recommended, 2 deferred to NICE and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Acute coronary syndrome (ACS) | Not Recommended | source |
| PHARMAC (New Zealand) | 30 Nov 2022 | Minor stroke or high risk TIA, prevention of atherothrombotic events | PTAC advice: Low · decision reached | source |
| HAS (France) | 22 May 2019 | Listing renewal (Transparency Committee) | SMR substantial | source |
| SMC (Scotland) | 10 Apr 2017 | Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of devel… | not recommended | source |
| AWMSG (Wales) | 7 Apr 2017 | Co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult pat… | outside AWMSG criteria | source |
15 further decisions for ticagrelor, across 8 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- clopidogrel — same ATC class B01A — Antithrombotics
Coverage: 20 decisions for ticagrelor from 9 agencies, 2011 to 2023. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.